92 -7 (81) 2025 - Sharipov A.T. - AUTOIMMUNITY DISORDERS IN INFANTILE CEREBRAL PARALYSIS

AUTOIMMUNITY DISORDERS IN INFANTILE CEREBRAL PARALYSIS

Sharipov A.T. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The levels of natural autoantibodies to neurospecific proteins were studied in 110 patients with cerebral palsy (main group) compared with a control group of practically healthy children of the corresponding age. Children with cerebral palsy demonstrate a significant (×1.6–2.7) and clinically significant increase in the spectrum of neurospecific autoantibodies, reflecting combined axonal-glial damage, demyelination and disruption of key neurotransmitter systems. These data reinforce the concept of an autoimmune contribution to the chronicity and heterogeneity of clinical manifestations of cerebral palsy and substantiate the feasibility of including these auto-ABs in a comprehensive biomarker panel screening for stratification of patients by risk of severe motor and cognitive outcomes and for early selection of candidates for immunotherapy (i.v. immunoglobulin, plasmapheresis, anti-B-cell drugs)

Key words: cerebral paralysis, autoantibodies, neurospecific proteins, immunoreactivity

First page

490

Last page

493

For citation:Sharipov A.T. - AUTOIMMUNITY DISORDERS IN INFANTILE CEREBRAL PARALYSIS//New Day in Medicine 7(81)2025 490-493 https://newdayworldmedicine.com/en/new_day_medicine/7-81-2025

List of References

  1. Alferova V., Gekht B., Poletaev A.B., Abrosimova A.A., Belikova L.P., Chumakova A.A., Nikolaeva T.Ya., Gusev E.I. Neurotropic natural autoantibodies of class IgG in the blood serum of patients with ischemic stroke // Journal of Neurology and Psychiatry named after S.S. Korsakov. - 2008. - Vol. 108, No. 1. - P. 56-60.
  2. Rasulova H.A., Azizova R.B. Natural neurotropic autoantibodies in the blood serum of patients suffering from epilepsy // Bulletin of the Russian Academy of Medical Sciences. - 2014. - No. 5-6. - P. 111-115.
  3. Uranova N.A., Kolomeets N.S., Vikhreva O.V., Zimina I.S., Rakhmanova V.I., Orlovskaya D.D. Ultrastructural pathology of myelinated fibers in the brain in continuously ongoing and paroxysmal schizophrenia. Korsakov Journal of Neurology and Psychiatry. 2017; 117(2): 104–9.
  4. Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D. S100P stimulates cell proliferation and survival via receptor for activated glycation products (RAGE) // J. Biol. Chem. – 2004. – Vol. 279 (7). – P. 5059–5065.
  5. Mohagheghi M., Alikhani M.Y., Taheri M., Eftekharian M.M. Determining the IgM and antibodies IgG titer against HSV1, HSV2 and CMV in the serum of schizophrenia patients. Hum. Antibodies. 2018; 26(2): 87–93. DOI: 10.3233/HAB-170325.
  6. Tanaka T., Matsuda T., Hayes L.N., Yang S., Rodriguez K., Severance E.G. et al. Infection and inflammation in schizophrenia and bipolar disorder. Neurosci Res. 2017; 115:59–63. DOI: 10.1016/j.neures.2016.11.002
  7. Dietsche B., Kircher T., Falkenberg I. Structural brain changes in schizophrenia at different stages of the illness: a selective review of longitudinal magnetic resonance imaging studies. SAGE J. 2017; 51(5): 500–8. DOI: 10.1177/0004867417699473
  8. Dickerson F., Jones-Brando L., Ford G., Genovese G., Stallings C., Origoni A. et al. Schizophrenia is associated with an aberrant immune response to Epstein - Barr virus. Schizophr. Bull. 2019; 45(5): 1112–19. DOI: 10.1093/schbul/sby164

    file

    download